All BioCurex announced on March 20, 2008 was that it had reached an agreement in principle to amend its original licensing agreement with Abbott Laboratories. It is obvious that nothing was binding at that point. Yesterday, BioCurex’s newly hired investor relations firm stated “If there are any further developments regarding the finalizing of the initial tentative agreement made on March 20, they will be made formally by the company.” Now, ask yourself where BioCurex’s newly hired investor relations firm came up with that answer? It had to come straight from BioCurex and confirmed that the agreement in principle to amend Abbott’s original license agreement has never been finalized and here it is over four months later. Now, ask yourself why it hasn’t been finalized yet? It has to be because Abbott doesn’t care whether it is ever finalized or not. Why would Abbott not care? It has to because Abbott has already exercised their option to give 90 days notice to BioCurex of the return of their license and that action nullifies all obligations, financial or otherwise, in the original license agreement. The main question here is whether BioCurex received a notice of return of a license from Abbott and failed to report that to its shareholders as required by SEC rules? kag
